For Fabry disease patients with amenable mutations, chaperone treatment is the appropriate approach, while for the rest of Fabry disease patients, combination therapy, such as ERT with substrate reduction therapy, might have a beneficial effect [28]. The gene discussed is ELF3; the disease is Fabry disease.